Stories

In the news

Press releases

Stories

Prime Insights

Media resources

Section divider

Stories 2019


2019

2018

2017

2016

December 12, 2019

January 2020 decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of January


November 20, 2019

Blue Plan partnership takes center stage at the SIU Forum

When it comes to finding and preventing FWA, Prime doesn’t work alone. Prime partners closely with Blue Plan clients to be at the forefront of fraud, waste and abuse (FWA) prevention efforts.


November 19, 2019

CMS Star Ratings Are Here

CMS Star ratings show a record 17 of Prime’s Medicare contracts earning quality bonus payments.


November 18, 2019

Improving the Medicaid member journey means removing barriers to care

Making the best Medicaid programs doesn’t happen overnight. It takes time to research how members access services and what might be a barrier to care. 


November 14, 2019

December decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of December.


November 8, 2019 

It must be a record!

Prime’s health outcomes team presents seven posters at AMCP Nexus.


November 4, 2019 

Prime Therapeutics named 2019 Business Excellence winner

Dakota County Regional Chamber honors Prime as dynamic area employer and vital corporate citizen.


Oct. 31, 2019

Offering the payer perspective on the opioid epidemic

Patrick Gleason, PharmD, shares how PBMs are helping to solve the opioid epidemic.


Oct. 30, 2019

AI World Conference: Catching a fraudster 

Jo-Ellen Abou Nader finds the needle in the fraud, waste and abuse haystack.


Oct. 28, 2019

Prime salutes its unsung heroes during National Pharmacists Month

Prime Therapeutics’ clinical review team is on the front line in fighting controlled substance abuse.


Oct. 23, 2019

Drug research for Prime’s P&T Committee becomes multi-purpose

Clinical research prep for Prime’s Pharmacy and Therapeutics (P&T) committee gets rave reviews from other departments at Prime who use the content as well.


Oct. 18, 2019

Step by step, drugs are evaluated for formulary  

For Prime’s Pharmacy and Therapeutics (P&T) Committee, evaluating drugs for formulary is about safety, efficacy, uniqueness and cost, in that order.


Oct. 16, 2019

Program featuring Prime pharmacists takes the gold at AMCP

Prime’s pharmacists are on the front lines of member outreach in Prime’s Smart Adherence program.


Oct. 14, 2019

November decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of November.


Oct. 11, 2019

The Pharmacy and Therapeutics (P&T) committee makes tough choices 

Members of Prime’s Pharmacy and Therapeutics (P&T) committee contribute to a lot of important decisions.


Oct. 9, 2019

Value based design in the news 

Finding value in value based design? Yes we have.


Oct. 7, 2019

Customer service: Putting people first 

During Customer Service Week (October 7-11), we thank our high-performing, flexible and engaged customer service teams.


Oct. 4, 2019

Unsung contributors to improved health outcomes and lower costs

The members of Prime’s Pharmacy and Therapeutics (P&T) committee meet at least four times a year to help keep Prime’s formularies in top form.

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.


Sept. 27, 2019

Prime’s P&T committee does amazing, not “obscure,” work for members

Prime’s commitment to member safety starts with the work of the Pharmacy and Therapeutics (P&T) committee.

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.


Sept. 26, 2019

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.

Prime’s Rae McMahan reveals winning strategies for total drug management

Prime manages evolving drug therapy landscape using powerful levers on both pharmacy, medical benefit.


Sept. 24, 2019

Prime offers real-time benefit check tool to deliver drug cost transparency at point of care, simplify prescription filling 

Electronic health records-compatible solution increases member savings and prescriber efficiency.


Sept. 24, 2019

Medicare clients and members rate Prime's performance

We asked, and they told us how we’re doing. And it’s very good news.



Sept. 13, 2019

October decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of October.


Sept. 9, 2019

Building a house, goodwill and teamwork with Habitat for Humanity

Prime employees put together another successful volunteering season with Habitat for Humanity.


August 22, 2019

Dakota Scott Board names Prime a 2019 Employer of Excellence

With this award, the Dakota-Scott Workforce Development Board recognizes Prime for excellence in employee retention, compensation and training practices.


August 12, 2019

Giving Medicaid the attention it deserves

Prime’s dedicated Medicaid management team makes it its mission to achieve both the lowest drug costs for our Medicaid clients and the highest quality of care for members.


August 15, 2019

September decisions expected from the FDA

A synopsis of new drugs expecting an FDA decision in the month of September. 


August 14, 2019

Prime moves up on Inc. Magazine’s Annual List of America’s Fastest-Growing Private Companies

For the 8th consecutive year, Prime appears on the Inc. 5000, ranking no. 1,073 with three-year revenue growth of 391 percent.


August 9, 2019

City of Bloomington recognizes Prime Therapeutics as a breastfeeding supportive workplace

Prime provides an inclusive work environment for our employees by supporting breastfeeding mothers in the workplace.


July 31, 2019

Prime showcases its controlled substance work at national conference

Pat Gleason and Jo-Ellen Abou Nader discuss the value of artificial intelligence using Prime’s integrated medical and pharmacy data.


July 22, 2019

When is a near flat trend a good trend? Right now.

Keeping drug trend in check is tough. When we can show our clients a Medicaid drug trend that’s virtually flat – three years in a row – that’s a huge victory.


July 17, 2019

Making nonadherence a nonissue

At Prime, we're working to keep nonadherence numbers down.


July 15, 2019

August decisions expected from the FDA

A synopsis of new drugs expecting an FDA decision in the month of August. 


July 8, 2019

Voter anxiety leads to flood of legislation

A look at the 2019 federal and state legislative trends related to drug pricing.


July 1, 2019

New Soliris indication approved for neuromyelitis optica spectrum disorder (NMOSD)

Staying on top of the drug pipeline so our clients don’t fall behind.


June 25, 2019

Value Frameworks like ICER help evaluate appropriate drug pricing when sky is the limit

Prime’s Gleason recently co-authored two health journal articles on the subject.


June 20, 2019

Overviews of high-profile drugs that impact health care

We stay on top of the drug pipeline so our clients don’t fall behind: Dupixient for severe asthma; Zolgensma for spinal muscular atrophy; CGRPs for migraines; Spravato for treatment-resistant depression; and Epidiolex for Lennox-Gastaut and Dravet syndromes. 

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.


June 17, 2019

July decisions expected from the FDA

A synopsis of new drugs expecting an FDA decision in the month of July.  


June 11, 2019

Prime's cost transparency pilots

Prime Therapeutics tests innovative cost transparency solutions to help lower drug costs, simplify prescription journey.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.


May 23, 2019

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.

Final FDA guidance is progress toward biosimilar access, competition

Once a biosimilar is designated as interchangeable, pharmacists may be able to automatically substitute the biosimilar for the reference brand — which should increase their utilization and may save health plans and their members money.


May 7, 2019

It’s number one, and that’s not a good thing

May is Arthritis Awareness month. Arthritis is the leading cause of disability in the United States and there are a few things you’ll want to know.


May 1, 2019

Health literacy. Better messaging. Better outcomes. 

With clear, simple messaging, can lead to better understanding. And this can help lead to lower pharmacy costs, better adherence and better outcomes.


April 26, 2019

Prime’s A-team: managing autoimmune specialty conditions

As specialty clinical program director for autoimmune conditions, Ramona Powell keeps a lot of balls in the air: 80 plus different diseases fit in this category. 


April 4, 2019

Prime + JDRF: A personal connection

For Kelley Loughrey, a life-threatening incident involving her son sent them straight to the hospital. But what came out of that experience is something so much more.


April 8, 2019

Building a career in the fast moving specialty field

Not every move in Molly Borchardt's career has been planned. But as her knowledge about hemophilia grows, she has leveraged that into opportunities and new contributions. 


March 25, 2019

Prime lawyer receives Minnesota Lawyer In-House Counsel award

Prime’s Amy Taber, senior legal counsel, was honored March 2019 in Minnesota Lawyer’s first In-house Counsel Awards. She received one of two awards given in the health care category.


March 13, 2019

"ke kiʻikoʻa" – the word "cancer" in Hawaiian

Back when he was in school, to help him prepare for his pharmacy boards, Jeremy Whalen took some extra rotations in oncology. In Hawaii. In January. Smart thinking. Climate aside, it did change his life.